Fosun Pharma and Qilu Pharmaceutical Jointly Top the Latest Consistency Evaluation Rankings

Recently, there has been a steady stream of news regarding the second batch of centralized procurement, with various regions proactively following suit. It seems increasingly likely that the second round of volume-based procurement will indeed be implemented by year-end. Complaining is a sign of immaturity; what is inevitable will inevitably come. All you can do is gain a comprehensive understanding of competing products that have passed the consistency evaluation and prepare for a decisive battle.

According to statistics from the Insight database, as of May 27, a total of 133 drug varieties had passed the consistency evaluation. Among them, 51 were from the list of 289 varieties, and 46 varieties were deemed to have passed the consistency evaluation.

Ranking of Enterprises by Varieties Passing the Consistency Evaluation

From a corporate perspective, Fosun Pharmaceutical and Qilu Pharmaceutical have the highest number of approved varieties, reaching 13 varieties; Huahai and Kelun follow closely behind.

Among the varieties with three or more approved generic equivalents, Tenofovir Disoproxil Fumarate Tablets, Amlodipine Besylate Tablets, and Metformin Hydrochloride Tablets remain major blockbuster products.

Consistency Evaluation BE Filing Ranking

BE studies serve as a critical milestone signal for companies preparing to submit applications for the consistency evaluation. The Insight database distinguishes between BE studies for the consistency evaluation of generic drugs and newly submitted BE studies.

As of May 27, Shanghai Pharmaceutical Group had the highest number of bioequivalence (BE) study filings for consistency evaluation, with a total of 39 drug varieties.

Ranking of Enterprises Deemed to Have Passed the Consistency Evaluation

According to statistics from the Insight database, as of May 27, a total of 461 companies had submitted applications for consistency evaluation, covering 367 drug varieties in total; among these, 87 had obtained approval numbers, and 46 varieties were deemed to have passed the consistency evaluation.

Qilu Pharmaceutical has the highest number of products deemed to have passed the consistency evaluation, with a total of six, accounting for approximately half of all evaluated products (13 in total).